R
Recludix Pharma
Developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries
About Recludix Pharma
Recludix Pharma, founded in 2019, is a biotechnology company with offices in San Diego, California, and Cambridge, Massachusetts. The company specializes in discovering small molecule drugs, which are tiny compounds that can enter cells easily and affect their function. These drugs are primarily aimed at treating cancer (oncology) and other specific medical conditions.
Read full description
Recludix Pharma operates in the pharmaceutical and biotechnology market, focusing on developing innovative treatments for targeted patient groups. This means they are working on creating drugs that are specifically designed to treat certain types of patients, making their treatments more effective and personalized.
The company is funded by venture capital, which means it receives financial support from investors who are looking to back promising new companies with high growth potential. This funding helps Recludix Pharma to conduct research and development (R&D) activities, which are crucial for discovering and developing new drugs.
Recludix Pharma's business model revolves around drug discovery and development. They invest heavily in R&D to identify new small molecule drugs, test their effectiveness and safety, and bring them to market. Once a drug is developed, the company can generate revenue through various channels, such as licensing agreements with larger pharmaceutical companies, selling the drugs directly, or partnering with other organizations for distribution.
In summary, Recludix Pharma is a biotech company focused on discovering small molecule drugs for cancer and other diseases, funded by venture capital, and generating revenue through drug development and partnerships.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 55
- Open positions
- 2
- Dealroom signal
- 72.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Recludix Pharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jul 2023 | $125M | $500M | Sanofi | ↗ |
| SERIES AOther financing | Nov 2021 | $60M | $240M | Westlake Village BioPartners · Access Biotechnology · NEA | ↗ |
Growth signals
Latest recorded traffic for Recludix Pharma is 3.7K monthly website visits, up 42.3% over the last three months. Recludix Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
NEA
Westlake Village BioPartners
Access Biotechnology
Sanofi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Recludix Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Recludix Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.